Get full text

Abstract

This study assessed cost-effectiveness of a potential anti-tick vaccine that would protect against both Lyme borreliosis (LB) and tick-borne encephalitis (TBE) in a highly endemic setting of Slovenia. A Markov model was developed to estimate cost-effectiveness of a vaccine with potential combined protection against LB and TBE from the societal perspective. The model expressed time in annual cycles, followed a target population through their lifetime, and applied an annual discounting of 3%. A target population entered the model in a susceptible state, with time dependent probabilities to acquire LB/TBE. Disease manifestations were either resolved within one cycle, or a patient developed LB/TBE sequelae. The vaccination consisted of initial immunization and one revaccination. Estimates of LB/TBE direct and indirect costs, and data on natural course of LB/TBE were obtained from Slovenian databases. Effectiveness of the vaccine with potential combined protection against LB/TBE was derived from studies on existing TBE and LB vaccines, while utility estimates were collected from various literature sources. A vaccine with potential combined protection against LB/TBE was predicted to have an incremental cost of €771,300 per 10,000 vaccinated persons, an incremental utility of 17QALYs and a base-case incremental cost-effectiveness ratio (ICER) of 46,061€/QALY. Vaccine cost, effectiveness and discount rates were identified as the most influential model parameters. A wholesale price for a vaccine shot of €9.13 would lead to cost savings followed by health gains for the vaccination strategy. The base-case ICER was below commonly accepted thresholds of cost-effectiveness, indicating that a combined LB/TBE vaccine might be a cost-effective option in Slovenia. With early Health Technology Assessment becoming increasingly important, this analysis still represents a rare example of cost-effectiveness assessment prior to market authorisation. Although obviously in such a situation some key parameters are unknown, our model sets up a tool to analyse pharmacoeconomic criteria that can help development of a cost-effective health technology, in this case a combined tick-borne diseases vaccine.

Cite

CITATION STYLE

APA

J., M., J.W.R., H., H., S., P., B., M.J., P., & F., S. (2019). Cost-effectiveness of a potential anti-tick vaccine with combined protection against Lyme borreliosis and tick-borne encephalitis in Slovenia. Ticks and Tick-Borne Diseases, 10(1), 63–71. https://doi.org/10.1016/j.ttbdis.2018.08.014 LK  - http://sfx.umd.edu/hs?sid=EMBASE&issn=18779603&id=doi:10.1016%2Fj.ttbdis.2018.08.014&atitle=Cost-effectiveness+of+a+potential+anti-tick+vaccine+with+combined+protection+against+Lyme+borreliosis+and+tick-borne+encephalitis+in+Slovenia&stitle=Ticks+Tick-borne+Dis.&title=Ticks+and+Tick-borne+Diseases&volume=10&issue=1&spage=63&epage=71&aulast=Mihajlovi%C4%87&aufirst=J.&auinit=J.&aufull=Mihajlovi%C4%87+J.&coden=&isbn=&pages=63-71&date=2019&auinit1=J&auinitm=

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free